The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

This publication has 8 references indexed in Scilit:

• Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
  Annals of Oncology, 1998
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
  Journal of Clinical Oncology, 1998
• 656: A phase III trial comparing vorozole (RIVIZOR™) versus aminoglutethimlde in the treatment of advanced postmenopausal breast cancer
  European Journal Of Cancer, 1997
• 643: Letrozole (FEMARA®), a new potent, selective aromatase inhibitor (AI): Superior to another AI, aminoglutethimlde (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy
  European Journal Of Cancer, 1997
• Significantly improved survival with 'arimldex' (anastrozole (A)) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC): Updated results of two randomised trials
  European Journal Of Cancer, 1997
• Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
  British Journal of Cancer, 1996
• Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
  Journal of Clinical Oncology, 1996
• A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
  European Journal Of Cancer, 1996